# PULSE BIOSCIENCES, INC. (PLSE) — capital_raise/atm_program [announced]
Source: SEC API (secapi.ai) · situation sit_1a1059dde3b8a525b2df · retrieved 2026-08-12T07:00:59.268Z

## Overview
Pulse Biosciences, Inc. is a medical device company that develops and commercializes surgical and medical instruments and apparatus.

Pulse Biosciences, Inc. entered into an equity distribution agreement with Mizuho Securities USA LLC on August 6, 2026, pursuant to which the Company may offer and sell shares of its common stock ($0.001 par value) having an aggregate offering price of up to $75,000,000. Under the agreement, Mizuho will use commercially reasonable efforts to sell shares at-the-market on The Nasdaq Capital Market or other existing trading markets, at prices prevailing at the time of sale or at negotiated prices. The Company will pay Mizuho a commission of up to 3.0% of the gross sales price of any shares sold, and will reimburse specified expenses. The offering is made pursuant to the Company's effective Form S-3 registration statement (File No. 333-293596), with a prospectus supplement filed on August 6, 2026.

## Terms
- Counterparty: Mizuho Securities USA LLC · Deal value: $75.0M · Consideration: stock

## Key dates
- Announced 2026-08-06

## Timeline
- 2026-08-06 · 8-K (0001437749-26-026351): 8-K - PULSE BIOSCIENCES, INC. — *Pulse Biosciences, Inc. is a medical device company that develops and commercializes surgical and medical instruments and apparatus.* Pulse Biosciences, Inc. entered into an equity distribution agreement with Mizuho Securities USA LLC on August 6, 2026, pursuant to which the Company may offer and sell shares of its common stock ($0.001 par value) having an aggregate offering price of up to $75,000,000. Under the agreement, Mizuho will use commercially reasonable efforts to sell shares at-the-market on The Nasdaq Capital Market or other existing trading markets, at prices prevailing at the time of sale or at negotiated prices. The Company will pay Mizuho a commission of up to 3.0% of the gross sales price of any shares sold, and will reimburse specified expenses. The offering is made pursuant to the Company's effective Form S-3 registration statement (File No. 333-293596), with a prospectus supplement filed on August 6, 2026.
  https://www.sec.gov/Archives/edgar/data/1625101/0001437749-26-026351.txt

## Citations
- 0001437749-26-026351 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000143774926026351